Abstracts from the ISSAID 2021 Periodic Congress

Table 1 (abstract P37). Pregnancy outcomes under canakinumab

	Age at pregnancy	Last cana dose before conception	Doses and duration of cana after conception	Date and type of delivery	Birth weight	APGAR score	Fetoplacental anomaly, IUGR, or developmental delay	Feeding	Current age of the child
1*	25 years	150 mg, 2 weeks	150 mg at 6 and 14 weeks	16 week, miscarriage	-	-	No phenotypic or chromosomal anomaly	-	-
2*	26 years	150 mg, 14 weeks	150 mg at 31 weeks and 4-to-6-weekly thereafter	37 week, C/S	2.9 kg	8,9,10	No anomaly, IUGR, or delay	Breastfed 16 months	2.5 years
3	28 years	150 mg, 4 weeks	150 mg 8-weekly throughout pregnancy	39 week, C/S	3.4 kg	9,10,10	No anomaly, IUGR, or delay	Breastfed 8 months	2 years

cana, canakinumab; C/S, Caesarean section; IUGR, intrauterine growth retardation. * the same patient

ISSN: 1546-0096